Beyond 2020, the global Peptide Therapeutics market is expected to eclipse $42 billion. This dramatic market increase is driven by both growing incidences of cardiovascular and metabolic diseases, and technological enhancements in peptide synthesis that include...
Controlled delivery formulations remain one of the favored tools for advancing the lifecycle of pharmaceutical products. A traditional strategy is to initially launch multiple daily doses of an immediate-release (IR) product, then reformulate into a once-daily...
There are a number of pharmacological and economical benefits to developing controlled and modified release drug products. Following the 505(b)(2) pathway allows companies to make modest changes to an already approved drug and get continued market exclusivity for a...
Having worked with many pharmaceutical and biotech companies over the last few years as the co-organizer of our annual Controlled & Modified Drug Release Summit, the need for many of them to explore opportunities and invest in controlled release technologies...
Recent Comments